Get all the latest news on coronavirus and more delivered daily to your inbox. Sign up here.Former New York Times reporter Alex Berenson, who has become a lightning-rod figure during the coronavirus crisis for his detailed criticisms of state lockdown measures, told Fox News' Brit Hume in an interview Monday that he thinks officials' emphasis on expanded…
Get all the latest news on coronavirus and more delivered daily to your inbox. Sign up here.Former New York Times reporter Alex Berenson, who has openly questioned the models informing the government's reaction to the coronavirus crisis, told Fox News' Brit Hume that states should "reopen schools as quickly as possible" while also questioning other elements of the…
Get all the latest news on coronavirus and more delivered daily to your inbox. Sign up here.Former New York Times reporter Alex Berenson, who has become one of the most well-known voices pushing back against the strategy of mass lockdowns to fend off the coronavirus, clashed this week with a VICE writer when a request for a…
Get all the latest news on coronavirus and more delivered daily to your inbox. Sign up here.Former New York Times reporter Alex Berenson -- who has quickly become of one of the key figures in a growing movement questioning the strategy to lock down large sections of the country in response to the coronavirus crisis -- is…
Published: October 30, 2026, 10:16 pm Several reports of children choking have led to an FDA warning against Once Upon A Time snacks. The warning covers all flavors, quantities, lots and dates of Once Upon A Farm Tractor Wheels Organic, Toddler Soft-Baked Bars. The FDA has received several reports that describe infants ages 1.5 to
The FDA has cleared the interleukin (IL)-23 inhibitor tildrakizumab (Ilumya) for the treatment of active psoriatic arthritis (PsA) in adults. Sun Pharma announced the approval on October 30. “As an IL-23 inhibitor administered exclusively by a healthcare provider, Ilumya is now an option for adults with active psoriatic arthritis who are unable to self-administer treatment
Millions of Medicare enrollees who buy stand-alone prescription drug plans will see their average monthly premiums rise by 50% in 2027, a new analysis finds. But enrollees can avoid the average increase — from $34 a month to $51 — by switching to lower-cost plans during the program’s open enrollment period, which runs through Dec.